Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T03513
|
|||||
| Target Name |
Dopamine receptor (DR)
|
|||||
| Synonyms |
Human dopamine receptor
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Restless legs syndrome [ICD-11: 7A80] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Neupro | Drug Info | Phase 4 | Restless legs syndrome | [2] | |
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | ABBV-951 | Drug Info | Phase 3 | Parkinson disease | [3] | |
| 2 | EVK-001 | Drug Info | Phase 3 | Diabetic gastroparesis | [4] | |
| 3 | ONC201 | Drug Info | Phase 2 | Glioma | [5], [6] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Agonist | [+] 1 Agonist drugs | + | ||||
| 1 | Neupro | Drug Info | [7] | |||
| Activator | [+] 1 Activator drugs | + | ||||
| 1 | ABBV-951 | Drug Info | [8] | |||
| Antagonist | [+] 3 Antagonist drugs | + | ||||
| 1 | EVK-001 | Drug Info | [1] | |||
| 2 | ONC201 | Drug Info | [6] | |||
| 3 | L-piperazino-3-phenyl-indane derivative 1 | Drug Info | [9] | |||
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 2 | ClinicalTrials.gov (NCT01976871) Switching From Oral Dopamine Agonists to Rotigotine (SWITCH). U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT04750226) Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease. U.S. National Institutes of Health. | |||||
| REF 4 | Clinical pipeline report, company report or official report of Evoke Pharma. | |||||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 7 | Rotigotine Transdermal Patch: A Review in Parkinson's Disease. CNS Drugs. 2019 Jul;33(7):707-718. | |||||
| REF 8 | Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Ann Neurol. 2021 Jul;90(1):52-61. | |||||
| REF 9 | Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.